Evidence map›Paper›PMID 35892470›Full record

ArticleInternational journal of neonatal screening2022

Newborn Screening by Genomic Sequencing: Opportunities and Challenges.

David Bick, Arzoo Ahmed, Dasha Deen, Alessandra Ferlini, Nicolas Garnier, Dalia Kasperaviciute, Mathilde Leblond, Amanda Pichini, Augusto Rendon, Aditi Satija and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of neonatal screening, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Genomics in Health and Biomedicine.Advances in experimental medicine and biology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Assessment of the variant prioritization strategy for genomic newborn screening in the Generation Study.Genetics in medicine : official journal of the American College of Medical Genetics · 2025
    Article
  14. Article
  15. Data-driven consideration of genetic disorders for global genomic newborn screening programs.Genetics in medicine : official journal of the American College of Medical Genetics · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. The value of large-scale programmes in human genomics.European journal of human genetics : EJHG · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

David BickGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.
Arzoo AhmedGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.
Dasha DeenGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.
Alessandra FerliniMedical Genetics Unit, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-8385-9870
Nicolas GarnierPfizer Inc., Collegeville, PA 19426, USA.
Dalia KasperaviciuteGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.
Mathilde LeblondGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.
Amanda PichiniGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.ORCID 0000-0002-1776-562X
Augusto RendonGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.ORCID 0000-0001-8994-0039
Aditi SatijaGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.ORCID 0000-0002-0674-0515
Alice Tuff-LaceyGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.
Richard H ScottGenomics England Ltd., Dawson Hall, Charterhouse Square, Barbican, London EC1M 6BQ, UK.
Genomics England · GBPfizer (United States) · USUniversity of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newborn screening for treatable disorders is one of the great public health success stories of the twentieth century worldwide. This commentary examines the potential use of a new technology, next generation sequencing, in newborn screening through the lens of the Wilson and Jungner criteria. Each of the ten criteria are examined to show how they might be applied by programmes using genomic sequencing as a screening tool. While there are obvious advantages to a method that can examine all disease-causing genes in a single assay at an ever-diminishing cost, implementation of genomic sequencing at scale presents numerous challenges, some which are intrinsic to screening for rare disease and some specifically linked to genomics-led screening. In addition to questions specific to routine screening considerations, the ethical, communication, data management, legal, and social implications of genomic screening programmes require consideration.

Indexed as

genomenewbornscreeningsequencing

Identifiers

PMID35892470
PMCPMC9326745
OpenAlexW4285733434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.